Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI311 in Inactive Thyroid-Associated Ophthalmopathy
NCT07152392Phase 4Recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Apr 2025
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of sycume in thyroid associated ophthalmopathy (TAO), sponsored by Shanghai Changzheng Hospital. Started Apr 2025; status: recruiting.
02
Drugs
sycume
03
Conditions
thyroid associated ophthalmopathy (TAO)
Beyond the preview
Go deeper on NCT07152392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07152392.